## Abbott India Limited (ABBOTINDIA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Abbott India Limited (ABBOTINDIA) is a pharmaceutical company listed on the Indian stock exchange on January 8, 2010.  The company operates within the Pharmaceuticals sector and holds a significant position within the Indian pharmaceutical market, known for its diverse range of healthcare products.  Further details on its market share and specific product portfolio are needed for a more comprehensive analysis.

**2. Market Data Analysis:**

| Metric                     | Value             | Notes                                                              |
|-----------------------------|--------------------|----------------------------------------------------------------------|
| Current Price              | ₹28,611.05        |  Down ₹442.80 (-1.52%) from the previous close.                     |
| Percentage Change (PChange) | -1.52%            | Negative daily change indicating bearish sentiment.                   |
| Pre-Open Activity          | ₹28,927           |  Slight increase from the previous close, but lower than the open. |
| Week High                   | ₹30,521 (Aug 30)   | Significant high compared to the current price.                     |
| Week Low                    | ₹22,000 (Dec 21)   | Significant low indicating recent volatility.                       |
| VWAP                       | ₹28,856.51        |  Slightly above the current price.                                  |
| Sector PE                  | NA                 | Not available.                                                      |
| Symbol PE                  | NA                 | Not available.                                                      |
| Delivery Percentage        | 44.49%            | Moderate delivery percentage, suggesting a mix of long-term and short-term investors. |
| Market Depth               | Poor               |  The provided order book data shows zero buy and sell quantities at all price levels, indicating poor market depth. This suggests low liquidity and potential for significant price swings. |


**3. Financial Performance:**

Insufficient data is provided to analyze quarterly and annual trends for revenue, expenses, profit after tax, and EPS.  Only one data point for financial results is available (Dec 2009 - Feb 2010), which is insufficient for trend analysis.  Further financial statements are required for a complete evaluation.  Key financial ratios (e.g., ROE, ROA, Debt-to-Equity) are also unavailable.

**4. Corporate Actions and Announcements:**

Abbott India has a history of consistent dividend payouts, including special dividends.  Recent dividends have been substantial (₹410 per share in July 2024, ₹180 + ₹145 in July 2023, etc.).  No other significant announcements are mentioned in the provided data.  The consistent dividend payouts are positive for long-term investors.

**5. Shareholding Patterns:**

| Date       | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|------------|--------------------------|--------|-----------------------------|-------|
| 31-Dec-2017 | 74.99%                    | 25.01% | 0.00%                       | 100.00%|
| 31-Mar-2018 | 74.99%                    | 25.01% | 0.00%                       | 100.00%|
| 30-Jun-2018 | 74.99%                    | 25.01% | 0.00%                       | 100.00%|
| 30-Sep-2018 | 74.99%                    | 25.01% | 0.00%                       | 100.00%|
| 31-Dec-2018 | 74.99%                    | 25.01% | 0.00%                       | 100.00%|

The provided data shows no significant changes in promoter and public shareholding over the observed period.  This suggests stability in ownership structure.  However, more recent data is needed for a complete picture.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices (₹30,521 and ₹22,000 respectively).  The CM Annual Volatility of 25.79% further confirms this high volatility.  The poor market depth adds to the risk, as large trades could significantly impact the price.  The risk-reward profile is currently skewed towards higher risk due to volatility and low liquidity.

**7. Advantages of Buying the Stock:**

* **Consistent Dividend Payouts:**  A history of substantial dividend distributions is attractive to income-seeking investors.
* **Stable Shareholding:**  The consistent shareholding pattern suggests a stable ownership structure.

**8. Disadvantages and Risks:**

* **High Volatility:**  The stock price is highly volatile, posing significant risk to short-term investors.
* **Low Liquidity:**  Poor market depth indicates low trading volume, making it difficult to buy or sell large quantities without significantly impacting the price.
* **Insufficient Financial Data:**  The lack of comprehensive financial data hinders a thorough assessment of the company's financial health and future prospects.

**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Don't Buy.** The high volatility and low liquidity make short-term trading extremely risky.  The current downward trend further strengthens this recommendation.

* **Medium-Term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The lack of sufficient financial data prevents a strong buy recommendation.  However, the consistent dividend payouts could offset some of the risk for long-term holders.  New investors should wait for more data.

* **Long-Term (1 year and beyond): Hold (if you have stock), Don't Buy (if you don't).**  The long-term outlook depends heavily on the company's future financial performance and the overall pharmaceutical sector's growth.  More data is needed to make a confident long-term assessment.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* **Financial Health:** 3/10 (Insufficient data)
* **Market Performance:** 4/10 (High volatility, negative recent trend)
* **Volatility and Risk:** 2/10 (High volatility, low liquidity)
* **Corporate Actions and Governance:** 8/10 (Consistent dividend payouts)
* **Shareholding Patterns:** 7/10 (Stable ownership structure)

**Analysis Score (out of 10): 6/10**

* **Completeness and utilization of all provided data:** 7/10 (Most data used, but significant gaps)
* **Accuracy and clarity of the analysis:** 6/10 (Analysis is clear, but limited by data availability)
* **Professional formatting:** 7/10 (Well-structured report)


**11. Professional Recommendation Summary:**

Due to the high volatility, low liquidity, and insufficient financial data, a strong buy recommendation cannot be made.  For short-term investors, the risk outweighs the potential reward.  Medium-term and long-term investors should consider holding if they already own the stock, but new investors should wait for more comprehensive financial data and a clearer market trend before investing.  Further research into the company's financial statements, competitive landscape, and future growth prospects is crucial before making any investment decision.
